Shares in Stratagene fell 15 percent for the week ended Tuesday. The firm's shares led decliners in the BCW Index for the third week in a row. Since the beginning of May, Stratagene's shares have lost nearly half their value, though the reasons for the drop remain unclear (see related article).

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.